Clinical Trials
22 trialsNCT06958939 2026-05-27
The Safety and Efficacy of S103 in the Treatment of Refractory Generalized Myasthenia Gravis
Tang-Du Hospital
Phase 1 Active not recruiting
NCT06680037 2026-05-18
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
TG Therapeutics, Inc.
Phase 1 Recruiting
NCT07526493 2026-05-12
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
Tongji Hospital
Phase 1 Recruiting
NCT07085676 2026-05-06
Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
Hadassah Medical Organization
Phase 1 Recruiting
NCT07556120 2026-04-29
Efficacy and Safety of HN2301 in Patients With Generalized Myasthenia Gravis (MG)
Shenzhen MagicRNA Biotechnology Co., Ltd
Phase 1 Not yet recruiting
NCT07304154 2026-04-21
A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
Gilead Sciences
Phase 1 Recruiting
NCT06626919 2026-02-25
A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
Arcellx, Inc.
Phase 1 Recruiting
NCT06220201 2026-02-10
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1 Recruiting
NCT07215650 2025-11-17
Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
Candid Therapeutics
Phase 1 Recruiting
NCT05451212 2025-11-10
Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis
Cabaletta Bio
Phase 1 Completed
NCT06371040 2025-09-15
Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis
Tang-Du Hospital
Phase 1 Recruiting
NCT07154095 2025-09-04
A Single-Center, Randomized, Open-Label, Two-Sequence, Two-Period, Crossover Study Comparing the Pharmacokinetics and Safety of Pyridostigmine Sustained-Release and Immediate-Release Tablets Following Single and Multiple Doses in Healthy Chinese Participants
West China Second University Hospital
Phase 1 Completed
NCT06688435 2025-08-06
A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia Gravis
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1 Recruiting
NCT06249438 2025-07-25
CAR-AID
RenJi Hospital
Phase 1 Recruiting
NCT04965987 2025-07-11
Oxaloacetate in Myasthenia Gravis
University of Kansas Medical Center
Phase 1 Withdrawn
NCT06869278 2025-06-11
A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1 Recruiting
NCT06978738 2025-05-18
UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
Changzhou No.2 People's Hospital
Phase 1 Not yet recruiting
NCT06759948 2025-01-06
KY2024-853
Huashan Hospital
Phase 1 Not yet recruiting
NCT05828225 2023-04-25
Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of Refractory Myasthenia Gravis
Zhejiang University
Phase 1 Unknown
NCT01828294 2019-04-03
SIMM
St. Louis University
Phase 1 Terminated
NCT00424489 2018-08-31
Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis
Northwestern University
Phase 1 Terminated
NCT01047761 2016-11-01
Exercise for Stable Myasthenia Gravis
Baltimore VA Medical Center
Phase 1 Unknown